Skip header and navigation

19 records – page 1 of 2.

Document Type
Table
Review Code
INF031801v017 RR Table
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Table
Review Code
INF031801v017 RR Table
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Nov 26; Document no.: INF031801v017 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST Table)
Similar Reviews
EOC011901 RR
EOC031001 RR
Review History
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents

INF031801v017 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
INF031801v017 ESR
Question Submitted
March 18, 2021
Date Completed
November 12, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Evidence Search Report
Review Code
INF031801v017 ESR
Question Submitted
March 18, 2021
Date Completed
November 12, 2021
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Infection Prevention and Control
Clinical Presentation
Immunity
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L., Howell-Spooner, B.. How effective are COVID-19 vaccines? 2021 Nov 12. Document no.: INF031801v017 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 70 p. (CEST rapid review report).
Review History
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
INF031801v017 RR
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF031801v017 RR
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Updated Key Findings
November 16, 2021
Centers for Disease Control and Prevention (CDC) recommended that any individuals who develop myocarditis/pericarditis after a dose of an mRNA COVID-19 vaccine should defer receiving a subsequent dose until additional safety data are available.
On 9th November, 2021, the CDC allows mix and match of booster shots in USA.
National Advisory Committee on Immunization (NACI) recommended boosters for other high-risk groups, including people 70 years of age and older and front-line health care workers who had a short period of time between their first two shots.
NACI also recommended boosters for people who received two doses of the Astra Zeneca vaccine, as the mRNA vaccines appear to offer better protection.
On 4th November, 2021, the United Kingdom became the first country to approve Pfizer’s competitorOK competitor Merck's COVID-19 pill, which is already under review at the Food and Drug Administration (FDA) after showing strong initial results. Other antivirals are under consideration including an agent from Pfizer (Paxlovid). While promising, caution should be taken with interpreting data from oral antivirals as currently, no published data exist and much conclusions are drawn off grey literature .
India’s Covaxin covid 19 vaccine by Bharat Biotech reported a vaccine effectiveness of 77.8% from a clinical trial. , 2021, a CDC reported vaccine efficacy of 90.9% with primary data from one phase II/III clinical trial in preventing symptomatic, laboratory-confirmed COVID-19 in children aged 5–11 years with or without evidence of previous SARS-CoV-2 infection.
Key Findings
November 2, 2021
October 21st, 2021 Pfizer Inc. and BioNTech announced results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 with a relative vaccine efficacy of 95.6%.
On 21st October, 2021, the advisory panel for the Centers for Disease Control and Prevention (CDC) said people who received Moderna and Johnson & Johnson (J&J) COVID-19 vaccines should receive a booster dose, and should continue with the original vaccine they recieved.
NACI’s latest guidelines suggest provinces should offer boosters to Canadians who received two doses of the Oxford-AstraZeneca vaccine or one dose of the Johnson & Johnson vaccine.
The US Food and Drug Administration (FDA) vaccine advisory group on 26th October 2021 approved the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 to 11 at a reduced dosage from the stanard dosing available for those over 12.
Therapeutic Goods Administration (Australia) has provisionally approved a third dose of the Pfizer (Comirnaty) vaccine for individuals 18 years or older. Pfizer (Comirnaty) is recommended as a single booster dose, irrespective of the primary COVID-19 vaccine used.
On 29th October, 2021, NACI issued new guidance "strongly" recommending booster shots for seniors 80 and older.
A survey at University of Oxford, UK, found that social media played a part in children aged 9 to 18 being more undecided than their older counterparts.
A report by the CDC found that the effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was 93% during the period of B.1.617.2 (Delta) variant dominance among children and adolescents aged 12–18 years.
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Clinical Presentation
Infection Prevention and Control
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Nov 26. Document no.: INF031801v017 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 96 p. (CEST rapid review report)
Review History
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF031801v018 ESR
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Evidence Search Report
Review Code
INF031801v018 ESR
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Infection Prevention and Control
Clinical Presentation
Immunity
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L. & Howell-Spooner, B.. How effective are COVID-19 vaccines? 2021 Nov 26, Document no.: INF031801v018 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 53 p. (CEST evidence search report).
Review History
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LTC042402-01 ESR
Question Submitted
April 24, 2020
Date Completed
April 28, 2020
Status
3. Completed
Research Team
Long Term Care
and suspected cases, and on-site enhancement of infection prevention and control. RESULTS: As of March 18
Document Type
Evidence Search Report
Review Code
LTC042402-01 ESR
Question Submitted
April 24, 2020
Date Completed
April 28, 2020
Status
3. Completed
Research Team
Long Term Care
Category
Administration
Healthcare Services
Subject
Facilities
Long Term Care
Palliative Care
Infection Prevention and Control
Family
Population
All
Clinical Setting
Cardiac unit
Emergency
ICU
Long Term Care
Medicine Unit
NICU
Oncology
Priority Level
Level 4 completed within 1 week
Cite As
Howell-Spooner, B; Dalidowicz, M; Boden, C. How is "compassionate visit" defined and operationalized in the context of an infectious outbreak or pandemic? 2020 Apr 28; Document no.: LTC042402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 7 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LTC042402 RR
Question Submitted
April 24, 2020
Date Completed
April 30, 2020
Status
3. Completed
Research Team
Long Term Care
Health Canada. Infection Prevention and Control for COVID-19: Interim Guidance for Long Term Care
Document Type
Rapid Review
Review Code
LTC042402 RR
Question Submitted
April 24, 2020
Date Completed
April 30, 2020
Status
3. Completed
Research Team
Long Term Care
Key Findings
Visitor restrictions in long-term care (LTC) during an outbreak or pandemic are implemented due to the perceived risk of transmission between residents or staff and visitors. · Social isolation and possible loss of care resulting from visitor restrictions in LTC may place residents at risk of poorer outcomes in terms of both physical and mental health, as well as distress to families and staff (see Saskatchewan LTC Network Family Perspective). · Visitor restriction policies typically allow visits for compassionate reasons that include end of life, critical care, and support of persons who require assistance beyond that provided by healthcare e.g. support for feeding, mobility, or behaviors, but specific detail on these is not consistent or clear. · Recent changes to visitation policies in Australia are less restrictive and allow brief visitations (end of table 1, noted in red font). · Although the majority of policies describe a need for flexibility and case-by-case assessment of visits deemed “essential”, the majority of policies are not clear in who is to conduct this analysis or the criteria that should be used to make these decisions. Visitation policies differ in detail regarding the number of visitors allowed at one time, total number of visitors allowed, visit duration, mobility within the home and location of the visit. · Remote and technology assisted visits are to be facilitated by LTC staff. · Infection control practices are enforced for visitors, and may include screening (e.g. temperature, symptoms, travel and contact history), prohibiting ill visitors, use of personal protective equipment (PPE), hand and cough hygiene. · Education of visitors and support for proper infection control practices is encouraged in the majority of policies.
Category
Administration
Healthcare Services
Subject
Facilities
Long Term Care
Palliative Care
Infection Prevention and Control
Family
Population
All
Clinical Setting
Cardiac unit
Emergency
ICU
Long Term Care
Medicine Unit
NICU
Oncology
Priority Level
Level 4 completed within 1 week
Cite As
Tupper, S; Ward, H; Howell-Spooner, B; Dalidowicz, M; Boden, C. How is "compassionate visit" defined and operationalized in the context of an infectious outbreak or pandemic in long-term care? 2020 May 1; Document no.: LTC042402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC011901-01 ESR
Question Submitted
January 19, 2021
Date Completed
January 21, 2021
Status
3. Completed
Research Team
EOC
, Infection Prevention & Control Cite As: Mueller, M.; Young, C. How safe are the Pfizer and Moderna
Document Type
Evidence Search Report
Review Code
EOC011901-01 ESR
Question Submitted
January 19, 2021
Date Completed
January 21, 2021
Status
3. Completed
Research Team
EOC
Category
Infection Prevention and Control
Subject
Vaccination
Risk
Infection Prevention and Control
Population
All adults
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Mueller, M.; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 21; Document no.: EOC011901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 31 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC011901 RR
Question Submitted
January 19, 2021
Date Completed
January 24, 2021
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC011901 RR
Question Submitted
January 19, 2021
Date Completed
January 24, 2021
Status
3. Completed
Research Team
EOC
Key Findings
Initial findings from RCTs of the two authorized COVID-19 vaccines (Pfizer-BioNTech and Moderna) reported that the vaccines are safe. However, subsequent reports show that the adverse and severe allergic reactions to these vaccines are higher than the general rates for vaccines.
Various regulatory agencies identify the risk for serious allergic reactions as low for the authorized vaccines, and they continue to monitor the vaccines’ safety closely.
Further investigations to make causal relationships with reported severe allergic reactions or deaths are needed.
Risks and benefits of receiving the vaccines should be discussed individually in vulnerable populations including pregnant or breast-feeding women, immunocompromised people, or frail elderly people.
Category
Infection Prevention and Control
Subject
Vaccination
Risk
Infection Prevention and Control
Population
All adults
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Azizian, A; Groot, G; Mueller, M; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 24; Document no.: EOC011901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LTC042201-02 ESR
Question Submitted
April 22, 2020
Date Completed
April 25, 2020
Status
3. Completed
Research Team
Long Term Care
and suspected cases, and on-site enhancement of infection prevention and control. RESULTS: As of March 18
Document Type
Evidence Search Report
Review Code
LTC042201-02 ESR
Question Submitted
April 22, 2020
Date Completed
April 25, 2020
Status
3. Completed
Research Team
Long Term Care
Category
Administration
Infection Prevention and Control
Subject
Infection Prevention and Control
Health Planning
Facilities
Long Term Care
Population
Aged (80+)
Other
Clinical Setting
Long Term Care
Priority Level
Level 3 completed within 2-3 days
Cite As
Dalidowicz, M; Boden, C. What environmental management and built environment factors influence a home’s ability to prevent or manage an ILI outbreak? AND What is the evidence for infection control practices (checklist items) for preventing or managing an ILI outbreak? 2020 Apr 25; Document no.: LTC042201-02 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LTC012501v2-01 ESR
Question Submitted
January 25, 2021
Date Completed
March 8, 2021
Status
3. Completed
Research Team
Long Term Care
& Prevention  Infection prevention and control and preparedness for COVID-19 in healthcare settings. [9
Document Type
Evidence Search Report
Review Code
LTC012501v2-01 ESR
Question Submitted
January 25, 2021
Date Completed
March 8, 2021
Status
3. Completed
Research Team
Long Term Care
Category
Infection Prevention and Control
Subject
Facilities
Vaccination
Long Term Care
Infection Prevention and Control
Population
Aged (80+)
Clinical Setting
Long Term Care
Priority Level
Level 2 One week (7 days)
Cite As
Mueller, M; Boden, C. What impact does COVID-19 vaccination have on visitation policies and transmission rates in LTC? 2021 Mar 8; Document no.: LTC012501v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 23 p. (CEST evidence search report).
Related Documents
Documents

LTC012501v2-01 ESR

Read PDF Download PDF
Less detail

19 records – page 1 of 2.